ELISpot And Fluorospot Assay Market: By Assay Type (ELISpot and FluoroSpot), By Application (Diagnostic, Research, and Drug Discovery), By End User (Hospitals & Clinical Laboratories, Research Institutes, and Pharmaceutical & Biotechnology Companies), and Geography

Elispot and Fluorospot Assay Market size was valued at USD 342.1 million in 2023 and poised to grow at a CAGR of 7.3% from 2024-2030. These assays are crucial tools in immunology, offering high sensitivity for detecting and quantifying cytokine-secreting cells at the single-cell level. Factors including the rising prevalence of chronic and infectious diseases, advancements in immunology research, and increasing focus on personalized medicine drive the market's growth. According to the World Health Organization, infectious diseases caused over 6.5 million deaths globally in 2022, underscoring the need for advanced diagnostic and research tools.

The COVID-19 pandemic has significantly accelerated market growth, with unprecedented demand for these assays in vaccine development and immunological studies related to SARS-CoV-2. However, the industry faces challenges such as high costs, technical complexity, and the need for skilled personnel. Additionally, concerns over standardization and reproducibility of results pose ongoing challenges to market players. Despite these hurdles, the ELISpot and FluoroSpot Assay market is expected to continue its growth trajectory, driven by technological innovations, increasing applications in drug discovery, and expanding use in clinical diagnostics.

Elispot and Fluorospot Assay Market Key Developments:

• In June 2022, BD and CerTest Biotec collaborated to create a molecular diagnostic test for the Monkeypox virus, a rare disease caused by a virus closely related to the smallpox virus. The collaboration aims to improve the diagnosis and management of Monkeypox infections. As part of the collaboration, the assay will leverage the BD MAX™ open system reagent suite to validate the CerTest VIASURE Monkeypox CE/IVD molecular test on the BD MAX™ System. The assay will be available for BD MAX™ users and may help advance understanding of the global spread of the disease.
• In April 2022, ProImmune Ltd. launched a B-cell ELISpot assay service. The B cell ELISpot assay is a method used to analyze the immune response of B cells, which play a critical role in the body's immune defense against infections, immunological modulators, vaccines, and therapeutic drugs. Researchers can assess the efficacy of vaccines or the potency of therapeutic drugs by measuring the number of B cells producing a specific antibody in response to a particular stimulus.